There is a particularly interesting table in the July 2012 Investor Presentation titled Extensive Pipeline of Partnering Opportunities. The table has three columns: Phylomer Platform Technology, In-house Activities & Partnerships and No. of Deal Discussions.
For instance there are currently eight deal discussions in relation to intractable extracellular targets. Phylogica has its own in-house program in this space called the Anti-CD40L program for Lupus & Rheumatoid Arthritis.
Within the presentation there are slides which focus upon our in-house programs including the CD40 ligand. Considerable research has been completed to date in identifying phylomers including "initiating preclinical studies of optimised phylomers".
Th value of these programs could be enormous considering the $100m+ milestones attached to deals already negotiated. It is quite conceivable that some of the deal discussions may revolve around phylomers already discovered by Phylogica to have drug like properties. Instead of starting from scratch, a deal focused upon an in-house program would be off to a flying start. The target markets for our own programs include rheumatoid arthritis, cancer and multi resistant hospital infections including 'gram negative' microbial species.
PYC Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)